4746-67-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2,3-Dihydro-1H-benzo[d]imidazole is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Medicinal Applications:
In the field of medicine, 2,3-dihydro-1H-benzo[d]imidazole is used as a compound with potential biological activity, being studied for its possible role in the treatment of various diseases and conditions.
Used in Organic Chemistry Research:
2,3-Dihydro-1H-benzo[d]imidazole is utilized as a research compound in organic chemistry, aiding scientists in understanding its chemical properties and exploring its reactivity in different chemical reactions.
Used in Industrial Applications:
Due to its unique chemical structure, 2,3-dihydro-1H-benzo[d]imidazole may be employed in various industrial applications, potentially including the development of new materials, catalysts, or other specialized uses that capitalize on its distinctive properties.

Upstream product

• 583-39-1 2,3-dihydrobenzimidazol-2-thione 
• 95-54-5 1,2-diamino-benzene 
• 1355363-17-5 N-methylene1,2-phenylenediamine 
• 18227-18-4 benzimidazole hydrochloride 

Downstream Products

• 18773-95-0 1-acetylbenzimidazole 
• 51-17-2 benzoimidazole 

Relevant academic research and scientific papers

Synthesis of N-heterocyclic carbene boranes via silver N-heterocyclic carbene complexes

The reaction of N-heterocyclic carbene (NHC) complexes of silver with BH3 or BEt3 was investigated. On treatment of IiPr·AgCl (1-AgCl) (IiPr = 1,3-diisopropylimidazol-2-ylidene) with two equivalents of NaBH

An efficient and environmental benign synthesis of 2-benzimidazoles and 2-benzothiazoles using CeCl3-NaI as catalyst

A one-pot condensation of an aldehyde with 1,2-phenylenediamine or 2-aminothiophenol in dimethyl carbonate at 100°C under O2 in the presence of catalytic amounts of CeCl3-NaI gave an imine intermediate, which cyclised and dehydrogenated to give 2-arylbenzimidazoles or 2-arylbenzothiazoles in good yields.

Inhibitors of the salicylate synthase (Mbti) from Mycobacterium tuberculosis discovered by high-throughput screening

A simple steady-state kinetic high-throughput assay was developed for the salicylate synthase MbtI from Mycobacterium tuberculosis, which catalyzes the first committed step of mycobactin biosynthesis. The mycobactins are small-molecule iron chelators produced by M. tuberculosis, and their biosynthesis has been identified as a promising target for the development of new antitubercular agents. The assay was miniaturized to a 384-well plate format and high-throughput screening was performed at the National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB). Three classes of compounds were identified comprising the benzisothiazolones (class I), diarylsulfones (class II), and benzimidazole-2-thiones (class III). Each of these compound series was further pursued to investigate their biochemical mechanism and structure-activity relationships. Benzimidazole-2-thione 4 emerged as the most promising inhibitor owing to its potent reversible inhibition.